Invention Grant
- Patent Title: CTLA4/PD1 targeted/immunomodulatory fusion proteins
-
Application No.: US16443973Application Date: 2019-06-18
-
Publication No.: US11028399B2Publication Date: 2021-06-08
- Inventor: Nagaraj Govindappa , Kedarnath Sastry , Maria Melina Soares
- Applicant: BIOCON LIMITED
- Applicant Address: IN Bangalore
- Assignee: BIOCON LIMITED
- Current Assignee: BIOCON LIMITED
- Current Assignee Address: IN Bangalore
- Agency: Olive Law Group, LLC
- Agent Marianne Fuierer
- Priority: IN1689/CHE/2012 20120430,IN1690/CHE/2012 20120430
- Main IPC: C07K14/00
- IPC: C07K14/00 ; A61K39/395 ; C07K7/08 ; A61K39/00 ; C12N15/62 ; C07K14/495 ; C07K14/65 ; C07K14/705 ; C07K16/28 ; C07K16/32 ; G01N33/68 ; A61K38/10 ; A61K38/17 ; A61K45/06 ; C07K14/71 ; C07K16/30 ; A61K48/00 ; C12N5/00 ; A61K38/00
Abstract:
The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
Information query
